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39 Abstract
40 Microvascular endothelial cell (EC) injury and the subsequent blood-brain barrier (BBB) 
41 breakdown are frequently seen in many neurological disorders, including stroke. We have 
42 previously documented that peroxisome proliferator-activated receptor gamma (PPARγ)-
43 mediated cerebral protection during ischemic insults needs Krüppel-like factor 11 (KLF11) as a 
44 critical coactivator. However, the role of endothelial KLF11 in cerebrovascular function and 
45 stroke outcome is unclear. This study is aimed at investigating the regulatory role of endothelial 
46 KLF11 in BBB preservation and neurovascular protection after ischemic stroke. EC-targeted 
47 overexpression of KLF11 significantly mitigated BBB leakage in ischemic brains, evidenced by 
48 significantly reduced extravasation of BBB tracers and infiltration of peripheral immune cells, 
49 and less brain water content. Endothelial cell-selective KLF11 transgenic (EC-KLF11 Tg) mice 
50 also exhibited smaller brain infarct and improved neurological function in response to ischemic 
51 insults. Furthermore, EC-targeted transgenic overexpression of KLF11 preserved cerebral tight 
52 junction (TJ) levels and attenuated the expression of pro-inflammatory factors in mice after 
53 ischemic stroke. Mechanistically, we demonstrated that KLF11 directly binds to the promoter of 
54 major endothelial TJ proteins including occludin and ZO-1 to promote their activities. Our data 
55 indicate that KLF11 functions at the EC level to preserve BBB structural and functional integrity, 
56 and therefore confers brain protection in ischemic stroke. KLF11 may be a novel therapeutic 
57 target for the treatment of ischemic stroke and other neurological conditions involving BBB 
58 breakdown and neuroinflammation.
59
60 Introduction
61 Stroke ranks as the fifth leading cause of death, and accounts for 1 out of every 20 deaths in the 
62 United States (7, 58). Ischemic stroke leads to cerebrovascular and neuronal damage, both of 
63 which contribute to ischemic injury and dictate stroke outcome (24, 66). Although studies have 
64 implied the effectiveness of neuroprotectants in animal stroke models (24, 32), there has been 
65 very little progress made in the past three decades concerning the successful translation of 
66 neuroprotective strategies to the clinical setting. The lack of clinical translation implies that 
67 focusing on neuroprotection only is insufficient. Non-neuronal cells and the local 
68 microenvironment of the surviving neurons could also serve as therapeutic targets to alleviate 
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70 of brain microvasculature and play critical roles in maintaining the integrity of the blood-brain 
71 barrier (BBB, a brain-specific microvascular structure) and cerebral homeostasis under 
72 physiological conditions (1, 5, 50). Cerebral ECs are tightly connected by adherens junctions 
73 (AJs) and tight junctions (TJs), including occludin, claudins, and junctional adhesion molecule 
74 (JAM), which are anchored to the actin cytoskeleton by scaffold proteins such as zonula 
75 occludens (ZO)-1, AF6, and cingulin. Together they form a diffusion barrier that selectively 
76 blocks the passage of most compounds through blood to brain compartments (4, 16, 39). When 
77 BBB integrity is compromised, proinflammatory factors may pass through the BBB to attract 
78 circulating immune cells to the injured brain, leading to secondary ischemic brain parenchymal 
79 injuries (15, 33-35, 46, 55, 60). Therefore, inhibition of BBB disruption through stabilizing TJs 
80 and protecting brain endothelium has become promising therapeutic strategies for ischemic 
81 stroke (18, 22, 45). 
82 Krüppel-like factors (KLFs) are a large family of zinc finger transcription factors that are known 
83 to trans-activate or trans-repress gene expression in various organisms (63). Recent studies have 
84 reported the involvement of KLF members in various developmental and pathological vascular 
85 processes (2, 52). A recent RNA sequencing study showed that in human endothelium, KLF11 
86 has modest mRNA expression (20). KLF11 has been reported to play functional roles in the 
87 regulation of cell growth and differentiation, cholesterol metabolism, and cell death (21, 25, 42, 
88 52). Moreover, population genetics studies have demonstrated that mutations in the KLF11 gene 
89 are strongly associated with type 2 diabetes (21, 42). Previous studies indicated that KLF11 
90 inhibits endothelial activation in response to inflammatory stimuli (19). In addition, vascular 
91 smooth muscle cell-selective deletion of KLF11 aggravates arterial thrombosis in mice (36). 
92 However, the role of KLF11 in cerebrovascular biology remains largely undetermined. 
93 A previous study by our group reported that KLF11 functions as a peroxisome proliferator-
94 activated receptor-γ coregulator to attenuate middle cerebral artery occlusion (MCAO)-induced 
95 ischemic brain injury (62). In conventional KLF11 knockout mice, we observed larger brain 
96 infarct, increased sensorimotor loss, aggravated BBB leakage, higher brain edema, and lower 
97 cerebral blood flow (CBF) following cerebral ischemic insult (53). These studies suggest KLF11 
98 plays a protective role in the pathogenesis of ischemic stroke. However, the molecular events and 
99 regulatory roles of endothelial KLF11 itself in stroke-induced cerebral EC injury and BBB 
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101 KLF11 stabilizes the cerebrovascular endothelial structure while simultaneously reducing stroke-
102 induced inflammatory events through preserving the integrity of TJs in cerebral ECs. 
103
104 Results
105 Generation and characterization of EC-selective KLF11 transgenic mice. ECs are major 
106 components of the BBB and are very sensitive to oxidative stress and ischemic insults (23). 
107 Previously, KLF11 expression was found to be significantly decreased in cultured mouse 
108 primary brain microvascular endothelial cells (BMECs) after 4 h or 16 h oxygen-glucose 
109 deprivation (OGD) treatment (Fig. S1A) as well as in isolated cerebral microvessels from 
110 C57BL/6J mice that were subjected to 1 h MCAO followed by 24 h reperfusion (Fig. S1B). We 
111 also reported that genetic deletion of KLF11 in mice significantly augmented MCAO-induced 
112 BBB disruption through exaggerating cerebrovascular permeability and edema (53). However, 
113 whether KLF11 maintains the integrity of the BBB at the very early stages (1-3 h) after ischemic 
114 insults, and whether endothelial KLF11 plays distinct roles in the pathogenesis of ischemic brain 
115 injury remain unknown. To explore the specific role of KLF11 in endothelial cells after ischemic 
116 injury, we generated transgenic mice with vascular endothelial cell-selective overexpression of 
117 KLF11 on a C57BL/6J background. The EC-specific KLF11 transgenic construct contains the 
118 Tie 2 promoter and Tie 2 enhancer (47, 64) to drive expression of the full-length KLF11 cDNA 
119 sequence (Fig. 1A). The Tie 2 promoter allows selective targeting of KLF11 to vascular ECs. 
120 The transgenic founder mice with KLF11 overexpression (EC-KLF11 Tg) were identified by 
121 genomic PCR genotyping (Fig. 1B). To confirm the overexpression of KLF11 in the brain 
122 microvasculature, we isolated cerebral microvessels from EC-KLF11 Tg and WT mouse brains. 
123 We found a significant upregulation of cerebrovascular KLF11 protein level in EC-KLF11 Tg 
124 mice than that of WT controls (Fig. 1C left). Moreover, KLF11 was not overexpressed in the 
125 cortical protein extracts from EC-KLF11 Tg mouse brain in comparison with WT controls (Fig. 
126 1C right). Of note, in sham-operated mice, no significant differences were observed in CD31-
127 labeled microvasculature of EC-KLF11 Tg mice compared to WT controls, as indicated by 
128 branch points, capillary numbers, and branch length (Fig. 1 D-E). We also noticed that regional 
129 CBF did not differ by transgenic overexpression of KLF11 in endothelium 15 minutes before 
130 ischemia, 15 minutes after ischemia, or 15 minutes after reperfusion (Fig. 3 D-E), suggesting that 
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132 structural (collateral) changes in the brains of EC-KLF11 Tg mice. Thus, EC-KLF11 Tg mice 
133 can be used as a powerful tool to investigate the functional role of KLF11 in vascular endothelial 
134 biology and BBB pathologies in vivo.
135
136 EC-selective KLF11 transgenic overexpression ameliorates post-ischemic cerebrovascular 
137 permeability. Next, we performed Evans Blue and TMR-Dextran extravasation assays to 
138 observe and quantify changes in BBB permeability. EC-KLF11 Tg and WT mice were subjected 
139 to 1 h MCAO followed by 1 h, 3 h, or 24 h reperfusion. The results showed that EC-targeted 
140 transgenic overexpression of KFL11 markedly reduced, but not completely blocked the leakage 
141 of both Evans blue dye and TMR-dextran into ischemic brain after 24 h reperfusion (Fig. 2 A-D). 
142 To assess BBB permeability at earlier stages (1-3 h) after ischemic insult, we also analyzed the 
143 extravasation of a small fluorescent tracer, Alexa 555 cadaverine (0.95 kDa), which was injected 
144 through the tail vein, and the relatively larger endogenous plasma IgG (150 kDa) into the 
145 ischemic brain parenchyma (48, 49). The extravasation of the small molecule cadaverine in both 
146 the ipsilateral cortex and striatum was detected as early as 1 h reperfusion, whereas endogenous 
147 IgG was detected in the same area at 3 h reperfusion (Fig. 2E). Compared with WT controls, EC-
148 KLF11 Tg mice consistently showed significantly reduced extravasation of cadaverine (at 1h, 3h, 
149 and 24h reperfusion; Fig. 2F) and IgG (at 3h and 24h reperfusion; Fig. 2G). These results suggest 
150 that early-onset BBB impairment occurred following ischemic insult and endothelial-specific 
151 KLF11 transgenic overexpression protects against MCAO-induced early-onset and progressive 
152 (late-onset) BBB impairments. Moreover, anti-MAP2 immunostaining indicated that the brain 
153 regions which present signs of BBB breakdown at earlier stages after MCAO progressed into 
154 infarct zones at 24 h after MCAO (Fig. 2E). Quantification analysis of anti-microtubule-
155 associated protein 2 (MAP2) immunostaining showed that EC-KLF11 Tg mice had significantly 
156 reduced brain infarction compared with WT controls (Fig. 2H). We further measured and 
157 quantified the water content in ipsilateral and contralateral hemispheres of EC-KLF11 Tg and 
158 WT mice 72 h after MCAO. The results demonstrated that brain water content in the ipsilateral 
159 hemisphere of EC-KLF11 Tg mice was significantly less than that in the WT group (Fig. 2I), 
160 whereas water content in the contralateral hemisphere from both groups showed no significant 
161 differences (Fig. 2I). It is known that blood neutrophils can migrate through an impaired BBB 
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163 damage and secondary expansion of ischemic brain parenchymal injury (49). We used 
164 immunohistochemistry methods to detect neutrophils with a labeled Ly-6B antibody (Fig. 2J). 
165 Quantification analysis of Ly-6B immunostaining confirmed that in comparison with WT 
166 controls, MCAO-induced increases in brain infiltration of Ly-6B+ neutrophils were significantly 
167 reduced in EC-KLF11 Tg mouse brains (Fig. 2K). Taken together, these results suggest that 
168 endothelial-selective KLF11 transgenic overexpression not only protects against ischemia-
169 induced BBB damage but also provides further neurovascular protection against ischemic stroke.
170
171 EC-targeted KLF11 overexpression reduces ischemic brain injury and improves short-
172 term neurological function. The protective role of EC-KLF11 overexpression against ischemic 
173 insult was further confirmed by 2% 2,3,5-triphenyltetrazolium chloride (TTC) staining in another 
174 cohort of mice, in which neurological deficits were also scored. Compared with WT controls, 
175 EC-KLF11 Tg mice presented much smaller cerebral infarcts (Fig. 3 A-B) and significantly 
176 reduced neurological scores (Fig. 3C), indicating better neurological outcome after stroke. Of 
177 note, regional CBF showed similar changes between EC-KLF11 Tg and WT mice 15 minutes 
178 before ischemia, 15 minutes after ischemia, or 15 minutes after reperfusion (Fig. 3 D-E). In 
179 humans, cerebral ischemia always leads to sensorimotor dysfunction. We then investigated 
180 whether EC-targeted KLF11 overexpression affects post-stroke functional recovery by a battery 
181 of three different behavioral tests: adhesive tape removal, foot fault, and rotarod tests before and 
182 up to 7 days following MCAO (Fig. 3 F-I). Compared with WT control mice, EC-KLF11 Tg 
183 mice showed better recovery of sensorimotor function: longer staying latency in the rotarod test 
184 (Fig. 3F), lower rate of fault steps in the foot fault test (Fig. 3G), and shorter touching or 
185 removing time in the adhesive tape removal test (Fig. 3 H-I). These cumulative findings suggest 
186 that endothelial-specific overexpression of KLF11 facilitates spontaneous sensorimotor recovery 
187 after ischemic brain insult.  
188
189 EC-selective KLF11 overexpression preserves the integrity of junctional proteins after 
190 ischemic brain injury. TJ proteins are essential for maintaining the integrity of the BBB (28). 
191 Therefore, we further examined the underlying mechanism of endothelial KLF11-mediated BBB 
192 protection in vivo. EC-KLF11 Tg and WT mice were subjected to 1 h MCAO followed by one or 
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194 MCAO and subjected to total RNA isolation and qPCR analysis (Fig. 4 A-B) or western blotting 
195 analysis (Fig. 4 C-E). Endothelial-targeted KLF11 transgenic overexpression significantly 
196 preserved the expression of TJ proteins, ZO-1 and occludin in ischemic brain tissue at both the 
197 mRNA (Fig. 4 A-B) and protein (Fig.4 C-E) levels, consistent with the protective role of EC-
198 KLF11 overexpression in MCAO-induced BBB damage. Reduction in ZO-1 and occludin 
199 expression in vascular endothelial cells (labeled by CD31) following ischemic brain insults were 
200 further confirmed by immunofluorescent staining (Fig. 4F). As expected, EC-KLF11 
201 overexpression markedly retained their in situ expressions (Fig. 4F). These results indicate that 
202 endothelial-targeted KLF11 overexpression robustly protected the structural integrity of the BBB.
203
204 EC-targeted KLF11 transgenic overexpression mitigates inflammatory activity in ischemic 
205 brain regions. Neuroinflammation following ischemic stroke contributes to BBB damage (57). 
206 To test whether EC-targeted KLF11 overexpression alleviates MCAO-induced inflammatory 
207 activities in the ischemic brain, we measured a panel of inflammatory mediators in the cortex of 
208 the ipsilateral brain hemisphere at one or three days after MCAO. The mRNA expression levels 
209 of six pro-inflammatory mediators: TNF-α, IL-1β, MCP-1, IL-6, ICAM-1, and P-selectin 
210 markedly elevated following MCAO, and EC-targeted KLF11 overexpression attenuated this 
211 elevation (Fig. 5 A-F). We then measured the expression of the abovementioned inflammatory 
212 factors using Quantikine ELISA kits. Consistent with our previous observations, the six 
213 inflammatory mediators all reduced in EC-KLF11 Tg mice when compared with WT controls 
214 following MCAO (Fig. 5 G-L). Taken together, these results demonstrate that KLF11 transgenic 
215 overexpression in endothelium mitigates post-stroke inflammatory responses. 
216
217 KLF11 alleviates OGD-induced BBB leakage in an in vitro BBB model. To further 
218 investigate endothelial KLF11-mediated BBB protection against ischemic insults, we employed 
219 a two-cell based in vitro BBB model. The co-culture system consists of mouse astrocytes that are 
220 seeded on the bottom of a 12-well plate and adenovirus-transduced mouse BMECs that are 
221 seeded on the polyester membrane of transwell inserts (Fig. 6A). The co-culture system was then 
222 subjected to ischemic-like insult of OGD for 16 h, followed by 2 h reoxygenation. 
223 Transepithelial/transendothelial electrical resistance (TEER) was measured to monitor the 
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225 adenovirus-mediated infection before being subjected to OGD, the barrier functional disruption 
226 induced by OGD was attenuated in the Ad. KLF11group when compared with Ad. LacZ control 
227 group (Fig. 6B). On the contrary, OGD-induced barrier functional disruption was worsened in 
228 the adenoviral KLF11 knockdown group (Ad. shKLF11) compared with Ad. shLacZ control 
229 group (Fig. 6C). Next, luminal-to-abluminal barrier permeability (paracellular permeability) of 
230 the small fluorescent tracer (3 kDa Dextran) was measured at indicated time points after OGD. 
231 When KLF11 was upregulated by adenovirus in mBMECs prior to OGD, leakage of the 3 kDa 
232 tracer was significantly reduced, but not completely blocked, at 2-8 h post-OGD reoxygenation 
233 (Fig. 6D). In contrast, when KLF11 was downregulated in mBMECs by adenovirus-mediated 
234 infection (Ad. shKLF11) prior to OGD, leakage of the 3 kDa tracer was significantly increased at 
235 2-24 h post-OGD reoxygenation compared to the Ad. shLacZ group (Fig. 6E). Based on the 
236 above observations, we conclude that KLF11 overexpression attenuates OGD-induced 
237 endothelial barrier functional disruption in vitro, while KLF11 knockdown reverses this effect. 
238
239 KLF11 inhibits OGD-induced disruption of junctional proteins in cultured brain 
240 microvascular endothelial cells. To dissect functional roles and molecular mechanisms of 
241 KLF11 in stabilizing BBB integrity in response to ischemic stimuli, mouse primary BMECs 
242 were subjected to ischemic-like insult of OGD for 16 h, followed by 24 or 48 h reoxygenation. 
243 We found adenovirus-mediated overexpression of KLF11 blocked OGD-induced upregulation of 
244 pro-inflammatory cytokines IL-6 and MCP-1 at both the mRNA (Fig. S2 A-B) and protein levels 
245 (Fig. S2 C-D). Moreover, OGD stimuli significantly reduced the expression of TJ proteins ZO-1 
246 and occludin in mouse BMECs (Fig. 7 A-D). As expected, adenovirus-mediated KLF11 
247 overexpression successfully preserved the expression of both TJ proteins at the mRNA (Fig. 7 A-
248 B) and protein (Fig. 7 C-D) levels, consistent with previous observations in EC-KLF11 Tg mice 
249 (Fig. 4). Immunocytochemical studies also confirmed decreased ZO-1 and occludin expression 
250 after 4h OGD treatment (Fig. 7E). This effect was markedly attenuated in mouse BMECs 
251 overexpressing KLF11 (Fig. 7E), indicating KLF11 overexpression preserves the integrity of 
252 tight junction proteins after OGD. 
253
254 KLF11 regulates the expression of tight junction proteins ZO-1 and Occludin at the 
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256 to bind to GC-rich target sequences on promoters (38). We analyzed mouse ZO-1 and occludin 
257 promoters and identified three potential KLF11 binding sequences on each respective promoter 
258 (Fig. 8A), suggesting KLF11 may transcriptionally regulate ZO-1 and occludin. To confirm that 
259 KLF11 regulates ZO-1 and occludin through direct interaction with predicted binding sequences 
260 located in the promoter regions of these two genes, we cloned the promoter region of mouse ZO-
261 1 and occludin, respectively into a dual-luciferase reporter vector (pGL4.10 [luc2]). We also 
262 clone the deleted promoters of mouse ZO-1 and occludin (without the three potential KLF11 
263 binding sites) into the pGL4.10[luc2] vector (Fig. 8B, 8E). We then co-transfected mouse bEnd.3 
264 cells with these luciferase reporter constructs and a Renilla luciferase control reporter vector 
265 (pRL-TK). We found adenovirus-mediated KLF11 overexpression significantly increased 
266 luciferase activity of the reporter constructs containing wild type ZO-1 (pGL4_mZO-1) and 
267 occludin (pGL4_mOccludin) promoter sequences (Fig. 8C, 8F), whereas adenovirus-mediated 
268 KLF11 knockdown significantly decreased the luciferase activity of these two promoter 
269 constructs (Fig. 8D, 8G). In addition, neither adenovirus-mediated KLF11 overexpression nor 
270 KLF11 knockdown affects the luciferase activities of the two deleted promoter constructs 
271 (pGL4_Δ mZO-1, pGL4_Δ mOccludin). Taken together, these results confirm that KLF11 
272 transactivates ZO-1 and occludin by directly binding to their promoter region.  
273
274 Discussion
275 This study investigated the protective function of endothelial KLF11 against BBB damage in a 
276 mouse ischemic stroke model. The results indicate that KLF11 transgenic overexpression in 
277 endothelium attenuates post-ischemic cerebrovascular permeability, brain water accumulation, 
278 and brain infarction, presumably through blocking the disruption of the junctional proteins, ZO-1 
279 and occludin. By preserving the integrity of the BBB after ischemic insult, EC-targeted KLF11 
280 overexpression effectively reduces the infiltration of neutrophils into brain parenchyma and the 
281 production of proinflammatory factors in the injured brain, thereby eliciting neurovascular 
282 protection against neurological deficits. Our results also demonstrate that KLF11 transactivates 
283 ZO-1 and occludin through direct binding to their promoters. Taken together, our findings 
284 suggest EC-targeted KLF11 transgenic overexpression is effective in mitigating BBB disruption 
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286 The functional involvement of KLF family members has been reported in various developmental 
287 and pathological vascular processes (2, 52). KLF2 has been demonstrated to regulate endothelial 
288 proliferation, migration, and angiogenesis (8, 9, 13). KLF2 has also been reported to regulate 
289 vasoreactivity and vascular tone (13, 14, 43). Another KLF family member, KLF4, has been 
290 reported as an endothelial regulator in response to pro-inflammatory stimuli (27) and shear stress 
291 (40). A study using EC-targeted KLF4 transgenic and conditional knockout mouse models 
292 demonstrated vascular anti-inflammatory and anti-atherothrombotic functions of KLF4 (68). 
293 KLF4 was also reported to activate VE-cadherin at the transcriptional level, and thereby maintain 
294 normal endothelial barrier function (11). In addition, KLF6 has been demonstrated to play 
295 functional roles in regulating vascular development, remodeling, and responses to injury (10, 12). 
296 KLF14 was reported to mitigate atherosclerosis through modulating hepatic ApoA-I production 
297 in mice (26). Moreover, KLF14 was demonstrated to reduce endothelial inflammation by 
298 inhibiting the NF-κB signaling cascade (30).  However, KLFs are less studied in the context of 
299 cerebrovascular biology and diseases such as cerebral ischemia. 
300 We have previously performed genome-wide screening for PPARγ coregulators, and identified 
301 KLF11 as a novel PPARγ coregulator (62). We further confirmed a physical interaction between 
302 PPARγ and KLF11, and the regulatory effects of KLF11 on PPARγ-mediated cerebrovascular 
303 protection in primary BMEC cultures and mouse brain after in vitro (OGD) and in vivo (MCAO) 
304 ischemic insults. Later (53), we provided direct evidence of KLF11 itself in the regulation of 
305 ischemic brain injury. We found that conventional KLF11 KO mice had larger brain infarcts, 
306 along with worsened neurobehavioral performance, increased edema, and greater BBB 
307 disruption compared with WT mice (53).  Our studies suggest KLF11 as an endogenous 
308 protective mediator of ischemic stroke. However, the regulatory role of vascular KLF11 and the 
309 underlying mechanisms of KLF11 itself in mediating protection against BBB leakage, especially 
310 at the early onset (1-3 h) following ischemic insult, remain unknown. 
311 In this manuscript, we found that KLF11 expression was significantly downregulated in cultured 
312 BMECs and mouse cerebral microvessels after in vitro (OGD) and in vivo (MCAO) ischemic 
313 insults (Fig. S1). Brain microvascular ECs are the major components of the BBB, and along with 
314 pericytes, astrocytes, perivascular microglia, and the basal lamina, they form the neurovascular 
315 unit (29, 31). Given the importance of brain microvascular ECs in the formation of the BBB as 
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317 targeted transgenic overexpression of KLF11 driven by the Tie-2 promoter. Our results have 
318 shown that KLF11 overexpression in ECs not only reduces MCAO-induced BBB permeability 
319 and disruption (Fig. 2) but also leads to better neurological outcomes (Fig. 3). Moreover, in our 
320 two-cell based in vitro BBB model, we determined that KLF11 overexpression effectively 
321 preserved endothelial barrier integrity following ischemic-like conditions (Fig. 6). These findings 
322 suggest that endothelial KLF11 contributes to its overall protective effects against ischemic 
323 insults, therefore opening the possibility of potential therapeutic applications for KLF11.
324 There are numerous well studied mechanisms that contribute to ischemic-induced BBB 
325 disruption, such as increased oxidative stress, vascular inflammation, activation of matrix 
326 metalloproteinases (MMPs), loss of BBB cellular components, and abnormal pathologies of 
327 endothelial tight junctions (33, 37, 44, 46, 49, 55, 60). A recent study demonstrated that MCAO-
328 induced early structural disruption in brain microvascular ECs, including actin stress fiber 
329 formation and redistribution of junctional proteins, resulted in impaired BBB integrity (49). This 
330 early BBB disruption further facilitates MMP-mediated (especially gelatinase B/MMP-9) 
331 degradation of EC tight junctions/basal lamina and the consequent infiltration of circulating 
332 immune cells, leading to further BBB breakdown and secondary expansion of ischemic injury  
333 (41, 49). In our current study, we found that EC-targeted KLF11 transgenic overexpression 
334 ameliorates MCAO-induced early (1-3 h) and late (24 h) onset of BBB impairment (Fig. 2E), 
335 through preserving the integrity of tight junction proteins, ZO-1 and occludin (Fig. 5). It remains 
336 to be determined whether and how endothelial KLF11 affects MMP-mediated late-stage BBB 
337 disruption.
338 Brain ECs express TJ proteins at relatively high levels, thereby maintaining low permeability 
339 between blood components and the cerebrospinal fluid (6). The three primary TJ proteins 
340 expressed in brain ECs, occludin, claudins, and JAM, are tethered to the actin cytoskeleton by 
341 scaffold proteins such as ZO-1, AF6, and cingulin (28). As a member of the zinc finger family of 
342 transcription factors, KLF11 binds to GC-rich regions on gene promoters (38). We analyzed the 
343 promoter regions of all TJ proteins, and discovered three KFL11 binding motifs on mouse ZO-1 
344 and occludin promoters. Further, we confirmed the direct binding of KLF11 to these promoters 
345 and transactivation activities on ZO-1 and occludin by dual-luciferase assays (Fig. 8). Although 
346 in the current study we did not take into consideration that TJs are known substrates of MMPs 
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348 further regulated by MMPs need further investigation. Moreover, increased transcytosis in CNS 
349 endothelial cells may also lead to BBB disruption (3). Ben-Zvi et al. reported that genetic 
350 deletion of major facilitator superfamily domain containing 2a that is specifically expressed in 
351 CNS ECs results in a leaky BBB due to increased transcytotic vesicles within ECs, without 
352 affecting tight junctions (6). In our studies, EC-KLF11 Tg mice preserved relatively intact TJs 
353 but still developed BBB breakdown to some extent after MCAO, suggesting the possible 
354 involvement of transcellular pathway. Whether KLF11 plays a role in transcytosis needs further 
355 investigation. 
356 Loosening of EC junctions due to ischemic insult facilitates the infiltration of circulating 
357 immune cells and inflammatory factors, thereby producing serious clinical consequences other 
358 than ischemic injuries, such as vasogenic edema and hemorrhagic transformation (49). We 
359 previously observed that KLF11 KO mice show aggravated brain edema after ischemic insult 
360 when compared with WT controls (53), whereas in the current study, EC-targeted KLF11 
361 transgenic overexpression alleviates edema in the ischemic brain (Fig. 2I). We also observed less 
362 infiltration of neutrophils into the ischemic brain of EC-KLF11 Tg mice (Fig. 2K). Moreover, 
363 the expression of six inflammatory factors (TNF-α, IL-1β, MCP-1, IL-6, ICAM-1, p-selectin) 
364 that are frequently upregulated after ischemic insult were found to be significantly reduced in the 
365 ischemic brain of EC-KLF11 Tg mice compared with WT controls (Fig. 5). This is consistent 
366 with our previous report that genetic deletion of KLF11 in mice further aggravated MCAO-
367 induced upregulation of IL-6 (53), a major stroke-related pro-inflammatory cytokine. Our 
368 observations are also consistent with one previous publication that demonstrated 
369 lipopolysaccharide (LPS)-induced endothelial inflammation can be inhibited by KLF11 (19). 
370 They reported that compared with WT mice, LPS-induced leukocyte rolling and adhesion on 
371 postcapillary venular endothelium were further augmented in KLF11 KO mice. In addition, the 
372 expression levels of VCAM-1 and E-selectin were significantly increased in the aortas of KLF11 
373 KO mice (19). Therefore, KLF11-triggered anti-inflammation mechanisms may contribute to its 
374 overall protective functions against BBB damage and ischemic neurovascular injuries. Taken 
375 together, our results demonstrate that endothelial KLF11-mediated improvements in BBB 
376 tightness or stabilization limited the infiltration of blood neutrophils and reduced the release of 
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378 caused by neuroinflammation. Also, the regulatory effects of vascular KLF11 on other blood 
379 immune cells need further attention.  
380 In conclusion, our study demonstrates that EC-targeted KLF11 transgenic overexpression 
381 mitigates both early and late BBB disruption through preserving the integrity of TJ proteins and 
382 hindering the progression of neuroinflammation, leading to an overall functional improvement 
383 after ischemic stroke. Our results may have potential clinical applications because cerebral 
384 endothelial barrier disruption is important contributor to several pathological processes in the 
385 brain, especially those associated with inflammatory brain disorders. Therefore, the findings of 
386 this study may be applied to other disease processes including but not limiting to ischemic stroke.
387
388 Materials and methods
389 All procedures using laboratory animals were approved by University of Pittsburgh Institutional 
390 Animal Care and Use Committee, and performed in accordance with the National Institutes of 
391 Health Guide for the Care and Use of Laboratory Animals. All mice were randomly assigned to 
392 various experimental groups using a lottery box. All surgical preparation, stroke outcome 
393 assessments, neurobehavioral tests and data analysis were performed in blinded manner. 
394 EC-KLF11 Tg and littermate wild-type control (WT) mice (male, 8-10 weeks-old, body weight 
395 23-25g) were housed in a temperature- and humidity-controlled animal facility with a 12 h 
396 light/dark cycle, and with unlimited access to food and water. Animals that did not show a more 
397 than 75% CBF reduction or a less than 60% reperfusion over baseline levels or died after 
398 ischemic induction (~10% of stroke animals) were excluded from further experimentation. In 
399 this study, we used 138 MCAO-operated mice (WT, n=69; EC-KLF11 Tg, n=69). Sham-
400 operated mice were used as controls (WT, n=28; EC-KLF11 Tg, n=28).
401 Generation of EC-selective KLF11 transgenic (EC-KLF11 Tg) mice. Transgenic mice with 
402 endothelial cell-selective KLF11 overexpression were generated as described (64). A 1539-bp 
403 DNA fragment containing a KLF11 coding sequence was PCR amplified from human genomic 
404 DNA using the primers 5’-GATATCATGCACACGCCGGACTTCGCAGGCC-3’ (Forward) 
405 and 5’-GATATCTCAGGCAGAGGCTGGCATGCTCACC-3’ (Reverse). The DNA fragment 
406 was then cloned into the EcoRV site of the pBluescript II SK (+) vector to generate a pBlue-
407 KLF11 plasmid. To generate the Tie-2 promoter-driven pBlue-KLF11 construct, we then 
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409 and the polyA plus full Tie-2 enhancer (10,367 bp) (a generous gift from Dr. Sato, (47)) into the 
410 Xba I/Not I cloning site on pBlue-KLF11 plasmid, respectively. The construct was injected into 
411 fertilized C57 mouse oocytes and implanted into pseudo-pregnant female mice. Transgenic 
412 founder mice were identified by PCR genotyping using primers 5’-
413 CTGTGCTCAGACAGAAATGAGAC-3’ (forward) and 5’-ATCATCTGGCAAAGGACAGG-
414 3’ (reverse). The PCR amplification conditions were 94 °C x 5 min, 40 cycles of 94 °C x 30 sec, 
415 55 °C x 30 sec, 72 °C x 80 sec, followed by 72 °C x 5 min. This produced a 1.2 kb DNA 
416 fragment that contains both plasmid and Tie-2 promoter sequences. EC-KLF11 Tg mice are 
417 viable, fertile, normal in size, and do not display any gross physical or behavioral abnormalities.
418 Mouse model of transient focal cerebral ischemia. Focal cerebral ischemia was induced in 
419 adult male mice (8-10-weeks-old, 25-30 g) by intraluminal middle cerebral artery occlusion 
420 (MCAO) as described previously (53, 59, 61, 67). Briefly, mice were anesthetized with 1.5-3% 
421 isoflurane (Henry Schein Animal Health). A 2-cm length of a 7-0 rounded tip nylon suture was 
422 gently advanced from the internal carotid artery up to the origin of the middle cerebral artery 
423 (MCA) until regional cerebral blood flow (rCBF) was reduced to less than 25% of baseline. 
424 After 60 minutes of MCAO, blood flow was restored by removing the suture, and mice were 
425 allowed to recover for 1-7 days. In sham-operated mice, the same surgical procedure was 
426 performed except for suture insertion. Changes in rCBF, arterial blood gases, mean arterial 
427 pressure, and heart rate were monitored in animals 15 min before, during, and 15 min after 
428 MCAO. Animals that did not show a CBF reduction of at least 75% over baseline levels were 
429 excluded from further experimentation. Approximately 90% survival rate was observed in EC-
430 KLF11 Tg or WT mice at 1-7 d after MCAO. Animals that died after ischemic induction were 
431 also excluded. The rectal temperature was controlled at 37.0 ± 0.5°C during surgery. 
432 Measurement of infarct volume, neurological deficits, and sensorimotor function. 2,3,5-
433 triphenyltetrazolium (TTC) staining was performed to measure brain infarct after MCAO in 
434 some mice. These mice were sacrificed, and the brains were harvested 24 h after MCAO. The 
435 forebrain was sliced into seven coronal sections, each 1 mm thick. Sections were stained with 
436 2% TTC in 0.9% NaCl for 20 min, followed by fixation with 4% paraformaldehyde in PBS. 
437 Infarct volume was determined with ImageJ (National Institute of Health) as the volume of the 
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439 Neurobehavioral deficits were determined by the adhesive removal test, foot fault test, and 
440 rotarod test 1-3 days before MCAO and also at 3, 5 and 7 days of reperfusion after MCAO (53, 
441 54, 59, 67). Following cerebral ischemia, mice were also tested for neurological deficits and 
442 scored on a 5-point scale: 0, no observable neurological deficits (normal); 1, failure to extend 
443 right forepaw (mild); 2, circling to the contralateral side (moderate); 3, falling to the right 
444 (severe); 4, mice could not walk spontaneously; 5, depressed level of consciousness (very 
445 severe).
446 Immunohistochemistry and image analysis. At different time points following MCAO, EC-
447 KLF11 Tg and WT mice were anesthetized with carbon dioxide and transcardially perfused with 
448 0.9% NaCl followed by 4% paraformaldehyde in PBS. Brains were harvested and cryoprotected 
449 in 30% sucrose in PBS, and frozen serial coronal brain sections (30 µm thick) were prepared on 
450 a cryostat (CM1900, Leica). Brain sections were blocked with 5% normal goat serum in PBS for 
451 1 h, followed by overnight incubation (4 °C) with the following primary antibodies: mouse anti-
452 MAP2 (1:200; EMD Millipore, Billerica, MA), rabbit anti-NeuN (1:500; EMD Millipore), rat 
453 anti-CD31 (1:200; BD Biosciences, San Jose, CA), mouse anti-ZO-1 (1:100; Invitrogen, 
454 Carlsbad, CA), rat anti-Ly-6B (1:100; Abcam, Cambridge, UK), rabbit anti-Occludin (1:100; 
455 Thermo Fisher Scientific, Waltham, MA) (Supplementary Table S1). Secondary antibodies: 
456 Cy3-conjugated goat anti-rat IgG, Alexa Fluor 488-conjugated goat anti-rabbit IgG, and goat 
457 anti-mouse IgG (all at 1:400; The Jackson ImmunoResearch Lab). Images were collected by 
458 confocal microscopy (FV1000-II; Olympus; Center for Biological Imaging, University of 
459 Pittsburgh Medical School) and processed in Adobe Photoshop for compositions (17). Five 
460 different sections from each animal were photographed, and six ROIs were randomly selected 
461 from the infarct core and inner infarct border, respectively, on each section. Infarct volume was 
462 measured on seven equally spaced MAP2-stained sections encompassing the MCA territory 
463 using ImageJ. Capillary densities were examined by counting the number of capillaries stained 
464 with the anti-CD31 antibody as previously described (56).
465 Quantification of BBB permeability/leakage after MCAO. For analysis of cerebrovascular 
466 permeability by Evans Blue extravasation, mice were injected with 100 µl of 4% Evans Blue 
467 (EB) (Sigma-Aldrich, St. Louis, MO) through tail vein 23 h after MCAO. After 1 h, mice were 
468 perfused with 0.9% NaCl, mouse brains were then removed and separated into ipsilateral and 
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470 (Sigma-Aldrich) and centrifuged for 45 min at 25,000 rcf. The supernatants were collected, and 
471 EB levels in each hemisphere were calculated using the formula: (A620 nm – (A500 nm + A740 nm) / 
472 2) / mg wet weight. Background EB levels in the nonischemic hemisphere were subtracted from 
473 the ischemic hemisphere ipsilateral to the MCAO.
474 For analysis of cerebrovascular permeability by intravenous injection and detection of 
475 fluorescent-labeled Dextran and fluorescent tracer, mice were subjected to tail vein injection of 
476 either Tetramethylrhodamine-Dextran (TMR-Dextran, 70 kDa; 0.1 mg/g body weight, 
477 Invitrogen) or Alexa Fluor 555-conjugated cadaverine (0.95 kDa; Invitrogen) 30 min before 
478 sacrifice. Mice were anesthetized and transcardially perfused with 0.9% NaCl followed by 4% 
479 paraformaldehyde in PBS. Mouse brains were collected and cryoprotected in 30% sucrose in 
480 PBS, and frozen serial coronal brain sections (30 µm thick) were prepared on a cryostat. Brain 
481 sections were visualized directly under a fluorescent microscope. In parallel, brain hemispheres 
482 were homogenized in 1% Triton X-100 (Sigma-Aldrich) in PBS and fluorescent intensity was 
483 quantified by a SpectraMax i3x plate reader (Molecular Devices, San Jose, CA) using 555-nm 
484 excitation and 580-nm emission.
485 To measure the extravasation of endogenous IgG, sections were blocked in avidin and biotin 
486 solution (two drops of avidin/biotin solution into 10 mL of PBS; Vector Laboratories, 
487 Burlingame, CA) for 15 min each, followed by blocking in 5% NDS for 1 h. Sections were then 
488 incubated with biotinylated anti-mouse IgG (1:500; Vector Laboratories) at 4 °C overnight. 
489 Sections were then incubated with Alexa 488 Streptavidin (1:1,000; The Jackson 
490 ImmunoResearch Labs). Whole-section images were acquired using an inverted Nikon 
491 fluorescence microscope. Six equally spaced sections encompassing the MCA territory were 
492 quantified for cross-sectional area of fluorescence. These areas were summed and multiplied by 
493 the distance between sections (1 mm) to yield a volume of leakage (in mm3).
494 Adenovirus-mediated gain- or loss- of- KLF11 expression in BMECs. To generate adenoviral 
495 vectors overexpressing KLF11 (19), the coding sequences of human KLF11 was PCR-amplified 
496 with primers 5’-ATGCACACGCCGGACTTCGCAGG-3’ (Forward) and 5’-TCAGGCA 
497 GAGGCTGGCATGCTCA-3’ (Reverse), and subcloned into the pCR8⁄GW⁄TOPO entry vector 
498 (Invitrogen). To generate adenoviral vectors for overexpressing LacZ, the coding sequences of 
499 Escherichia coli LacZ were PCR amplified with primers 5’-
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501 TTATTTTTGACACCAGACCAACT-3’ (Reverse), and subcloned into the pCR8⁄GW⁄TOPO 
502 entry vector (Invitrogen). After sequencing, the LR recombination reactions were carried out 
503 between the entry clone pCR8⁄GW⁄TOPO/KLF11 and the destination vector pAd/CMV/V5-
504 DEST according to the manufacturer’s protocol (Invitrogen). For knockdown experiments, an 
505 siRNA oligo, which targets a region 100% conserved between human and mouse, was purchased 
506 from Invitrogen. To prepare adenovirus-containing shRNA for KLF11 or LacZ, synthesized 
507 oligos were annealed and inserted into the BLOCK-iT U6 entry vector. The U6 promoter and 
508 shRNA were cloned into the adenoviral plasmid pAd/BLOCK-iT-DEST according to the 
509 manufacturer’s instructions. The sequences for shRNA were as follows: 
510 shKLF11, 5′-CACCGGGTAGACTTTTCCCGAAGGCGAACCTTCGGGAAAAGTCTACC-3′, 
511                  5′-AAAAGGTAGACTTTTCCCGAAGGTTCG CCTTCGGGAAAAGTCTACCC-3′.
512 shLacZ,    5′-CACCGCTACACAAATCAGCGATTTCGAAAAATCGCTGATTTGTGTAG-3′, 
513                  5′-AAAACTACACAAATCAGCGATTTTTCGAAATCGCTGATTTGTGTAGC-3′.
514 To package the adenoviruses, adenoviral vectors were linearized with PacI and transfected into 
515 HEK293 AD cells using Lipofectamine 2000. The recombinant adenoviruses were purified by 
516 CsCl2 density gradient ultracentrifugation. Adenovirus genomic DNA was purified with 
517 NucleoSpin Virus Kit (Macherey Nagel), the adenovirus titration was determined using the 
518 Adeno-X™ qPCR Titration Kit (Clontech). The generated adenovirus was used to infect BMECs 
519 for 48-72 h.
520 Two cell based in vitro BBB model. Mouse astrocytes were purchased from Sciencell research 
521 laboratories (M1800-57). Astrocytes (2-8 passages) were grown in astrocyte medium (AM-a 
522 1831; Sciencell) and were seeded in a regular 12-well plate at 37 ºC in a humidified incubator 
523 until reaching confluence. Transwell chamber inserts with PET membranes (0.4 µm pore; 
524 Corning) were coated with collagen type IV (0.3 mg/ml) and fibronectin (0.5 mg/ml). Mouse 
525 BMECs were seeded onto the membrane at a density of 1 x 105 cells per insert. The inserts were 
526 then placed into the 12-well plates containing confluent astrocytes (Figure 7A) and co-cultures 
527 were maintained in endothelial growth medium (M1168; Cell Biologics) at 37 ºC in a humidified 
528 incubator overnight. The inserts seeded with mBMECs were then separated from the co-culture 
529 system and mBMECs were infected with either Ad. LacZ/Ad. KLF11 or Ad. shLacZ/Ad. 
530 shKLF11 in endothelial cell infection medium without phenol red and antibiotics (M1168PF; 
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532 confluent astrocytes and co-cultures were maintained in endothelial growth medium to reach 
533 confluence. 
534 Changes in transendothelial electrical resistance (TEER) at designated time points or conditions 
535 were used to detect permeability changes in the BBB. The reading of total resistance (RTotal) was 
536 measured with an Epithelial Volt/Ohm Meter (WPI, FL) at room temperature. The value of each 
537 sample (RTEER) was corrected by the reading of an empty coated-insert cell (RBlank) and 
538 calculated with the polyester membrane area (SMembrane) using the following formula and TEER 
539 values were reported in units of Ω-cm2:
540 RTEER = (RTotal – RBlank) x SMembrane
541 To assess paracellular permeability, Dextran Alexa Fluor 488 (3,000 MW) was added to the 
542 luminal chamber at a concentration of 1µg per 1ml medium. At 0.5h, 1h, 2h, 4h, 8h and 24h after 
543 OGD treatment, 50 µl medium was collected from the abluminal chamber. Fluorescence 
544 intensity was measured with a SpectraMax i3x Multi-Mode Detection Platform. The 
545 accumulated fluorescence intensity of abluminal Dextran Alexa Fluor 488 was measured at each 
546 time point and corrected by the respective blank (same treatment without adding Dextran in the 
547 luminal). Relative fluorescence unit (RFU) was recorded.
548 Cerebral microvessel isolation. Cerebral microvessels from mouse brain were isolated for 
549 determining the expression of KLF11, as previously described with modification (61). Briefly, 
550 EC-KLF11 Tg and littermate WT control mice were anesthetized with carbon dioxide and 
551 transcardially perfused with ice cold 0.9% NaCl. The brain was immediately removed from the 
552 skull and immersed in ice cold PBS. Brainstem, meninges and pia vessels were quickly removed, 
553 and the brain was cut into 1mm block and transfer to a 15 mL Dounce Tissue Grinder Tube 
554 (Kimble Chase, TN) with 5 mL buffer TE (a mixture of 0.25% Trypsin-EDTA and DMEM 
555 (Invitrogen, CA) at 1:1). The brain was homogenized by 5 strokes with a small clearance pestle. 
556 The homogenate was mixed with another 5 mL of buffer TE and incubate at 37 °C for 1 h with 
557 occasional agitation. After triturating 10-20 times with a 5 mL pipette, the creamy texture was 
558 centrifuged at 500 x g for 10 min at room temperature. The pellet was collected and dissolved in 
559 8 mL HBSS (Invitrogen, CA) by mixing twice with a 5 mL pipette, and the homogenate was 
560 suspended in 11 mL HBSS dissolved 25% BSA by gently triturate 5 times with a 10 mL pipette. 
561 The homogenate was centrifuged at 3,000 x g for 15 min at 4 °C to separate the lipid and the 
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563 centrifuge at 1,800 x g for 10 min. The pellet was rinsed with 1 mL PBS, transferred to a 1.5 ml 
564 centrifuge tube and spun down at 16,000 x g for 1 min. The final microvessel pellet was stored at 
565 -80 °C freezer until use. 
566 Brain water content. Brain water content was measured by the dry-wet method as described 
567 previously (53). Following MCAO, mice were sacrificed by exposure to CO2. The weights of the 
568 ipsilateral and contralateral hemispheres were recorded separately as wet weights. The dry 
569 weights of the ipsilateral and contralateral hemispheres were obtained after being heated at 100 
570 °C in an oven for 24 h. Brain content was calculated by the following formula: brain content = 
571 (wet weight - dry weight)/wet weight x 100%.
572 Cell cultures and oxygen-glucose deprivation (OGD). Mouse primary brain microvascular 
573 endothelial cells (mBMECs) were purchased from Cell Biologics (C57-6023). Mouse brain 
574 microvascular endothelial cells, bEnd.3 were purchased from American Type Culture Collection 
575 (CRL-2299, ATCC, Manassas, VA). Mouse BMECs and bEnd.3 cells (2-8 passages) were 
576 grown to 85-95% confluency before using for studies. To mimic ischemia-like conditions in 
577 vitro, mouse BMEC cultures were exposed to OGD for up to 16 h. Briefly, culture medium was 
578 replaced with deoxygenated glucose-free Dulbecco’s Modified Eagle Media (DMEM; Gibco, 
579 Grand Island, NY), and cultures were flushed with 95% N2 and 5% CO2 for 5 min in a Billups-
580 Rothenberg modular incubator chamber (Del Mar, San Diego, CA). The modular incubator 
581 chamber was then sealed and placed in a water-jacketed incubator (Forma, thermo Fisher 
582 Scientific, Waltham, MA) at 37 ˚C for the indicated period of time in each experiment before 
583 returning to humidified 95% air and 5% CO2 and glucose-containing medium (62, 67).
584 Immunocytochemistry. Mouse BMEC cells were seeded in 4-chamber polystyrene vessel tissue 
585 culture treated glass slides (Corning, NY) and infected with Ad. LacZ or Ad. KLF11. Seventy-
586 two hours after infection, BMEC cultures were subjected to OGD treatment and reperfusion for 
587 indicated time points. The cells were then fixed in 4% paraformaldehyde followed by blocking 
588 with 5% normal goat serum in PBST for 1 h at room temperature. The cells were then incubated 
589 with the following primary antibodies overnight at 4 °C: mouse anti-ZO-1 (1:100; Invitrogen, 
590 Carlsbad, CA), rabbit anti-Occludin (1:100; Thermo Fisher Scientific, Waltham, MA). After 
591 rinse in PBS, cells were incubated with secondary antibodies: Alexa Fluor 488-conjugated goat 
592 anti-rabbit IgG, and goat anti-mouse IgG (all at 1:400; The Jackson ImmunoResearch 
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594 mounted with antifade Vecta-Shield solution (Vector Laboratories). Images were collected on an 
595 Olympus FV1000-II confocal microscope and processed in Adobe Photoshop for compositions 
596 (17). Immunofluorescence intensities of ZO-1 and occludin were quantified by ImageJ. Three 
597 ROIs were randomly selected from each chamber, and 2-3 chambers were quantified for each 
598 experimental condition in each independent culture.   
599 Molecular cloning. The pGL4.10[luc2] vector was purchased from Promega. To make 
600 pGL4_mZO-1 and pGL4_mOccludin promoter reporter constructs, a 1,013 bp fragment of the 
601 promoter region of mouse ZO-1 or a 1,014 bp fragment of mouse occludin promoter region 
602 containing the putative KLF11 binding sequence was PCR-amplified from mouse genomic DNA 
603 using primers 5-CGAGACGCTAGCCTTGACTTTGAAACCTTAATTGATG and 5-
604 CTGGACCTCGAGGCAAAACCTGCCGGACCGGGCCACT, or 5-
605 CGAGACGCTAGCAGATAGTTAACTAACAAGAACTAAAATCTC and 5-
606 CTGGACCTCGAGCCTACCCCCGGGCATGCGCACCAATT. Both promoter fragments were 
607 then subcloned into the pGL4.10[luc2] vector, respectively. Mutant promoter constructs where 
608 all three putative KLF11 binding sequences were deleted were generated by QuikChange XL 
609 Site-directed Mutagenesis kit (Stratagene, Santa Clara, CA) (64). All constructs were validated 
610 by DNA sequencing (Genewiz, South Plainfield, NJ). NCBI RefSeq ID: ZO-1 (mouse): 
611 NP_001157046.1, occludin (mouse): NP_001347465.1. Supplementary Table S2.
612 Dual-luciferase reporter assays. Mouse bEnd.3 cells (ATCC, Manassas, VA) were seeded at 
613 0.5 x 105 cells/well in 24-well plates. After overnight incubation, cells were infected with 
614 different adenoviruses aimed at achieving KLF11 overexpression or knockdown. The cells were 
615 also co-transfected with pGL4_mZO-1/ΔmZO-1 or pGL4_mOccludin/ΔmOccludin luciferase 
616 reporter vector and a Renilla luciferase control reporter vector (pRL-TK; Promega), along with 
617 Lipofectamine 2000 (Invitrogen) for 5 h. Luciferase activity was measured 48 h after transfection 
618 by Dual-Luciferase assay kits (Promega) using a SpectraMax i3x Multi-Mode Detection 
619 Platform. Individual luciferase activity was normalized to the corresponding Renilla-luciferase 
620 activity (62, 64). 
621 Quantitative real time PCR. Total RNA was isolated from BMEC cultures or cerebral cortex 
622 by using RNeasy Mini Kit (Qiagen, Valencia, CA) or Trizol (Invitrogen, Carlsbad, CA). 
623 Quantitative real-time reverse-transcriptase polymerase chain reaction (RT-PCR) was carried out 
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625 SYBR green supermix (Bio-Rad, Hercules, CA). Specific primers used for the reactions are ZO-
626 1 Forward, 5’-gccgctaagagcacagcaa-3’; ZO-1 Reverse, 5’-tccccactctgaaaatgagga-3’. Occludin 
627 Forward, 5’-tgaaagtccacctccttacaga-3’; Occludin Reverse, 5’-ccgcataaaaagagtacgctgg-3’. TNF-α 
628 Forward, 5’-ctcctcacccacaccgtcagc-3’; TNF-α Reverse, 5’-aacacccattcccttcacagagca-3’. IL-1β 
629 Forward, 5’-aggagaaccaagcaacgacaaaatac-3’; IL-1β Reverse, 5’-tggggaactctgcagactcaaact-3’. 
630 MCP-1 Forward, 5’-gcaccagcaccagccaactctcact-3’; MCP-1 Reverse, 5’-cattccttcttggggtcagcacag-
631 3’. IL-6 Forward, 5’-agttgccttcttgggactga-3’; IL-6 Reverse, 5’-tccacgatttcccagagaac-3’. Icam-1 
632 Forward, 5’-ttcacactgaatgccagctc-3’; Icam-2 Reverse, 5’-gtctgctgagacccctcttg-3’. P-selectin 
633 Forward, 5’-gtccacggagagtttggtgt-3’; P-selectin Reverse, 5’-aagtggtgttcggaccaaag-3’. 
634 Cyclophilin Forward, 5’-actcctcatttagatgggcatca-3’; Cyclophilin Reverse, 5’-
635 gagtatccgtacctccgcaaa-3’ (Supplementary Table S3). The relative mRNA expression was 
636 normalized to cyclophilin RNA levels. PCR experiments were repeated 3 times, each using 
637 separate sets of cultures (53, 59, 67).
638 Western blot analysis. Samples from the 0.9% NaCl perfused mouse cerebral cortex or cultured 
639 mBMECs were homogenized in T-PER Tissue Protein Extraction Reagent (Pierce, IL) 
640 containing Mini Protease Inhibitor Cocktail (cOmpleteTM, Sigma) by Dounce Tissue Grinder or 
641 sonication for 30 seconds with 30% pulse on ice respectively. The tissue or cell lysates were 
642 centrifuged  at 10,000 x g for 5 min to pellet tissue or cell debris. Then supernatants were 
643 collected to measure protein concentrations by using the Bio-Rad Protein Assay (Bradford, Bio-
644 Rad). As described previously (53, 59, 67), equal amounts of protein were loaded into 4-15% 
645 precast gels (Bio-Rad) and transferred to polyvinylidene difluoride (PVDF, Bio-Rad) 
646 membranes. Membranes were blocked for 1 h with TBS/0.1%-Tween buffer plus 5% (w/v) non-
647 fat dried milk and incubated overnight at 4 °C with primary antibodies diluted in the same 
648 blocking buffer. Membranes were then incubated with secondary antibodies diluted in blocking 
649 buffer for 1 h and developed using a Pierce® ECL Western blotting detection kit (Thermo 
650 Scientific) and Amersham High-Performance Chemiluminescence Films (GE Healthcare). 
651 Various primary antibodies were used and are listed in Supplementary Table S1, including 
652 mouse anti-KLF11 (1:500; NovusBio), rabbit anti-occludin (1:1,000; Invitrogen), rabbit anti-ZO-
653 1 (1:250; Abcam), and mouse anti-β-actin (1:2000; Sigma-Aldrich). 
654 Enzyme-linked immunosorbent assay (ELISA). Cerebral cortices of mice were collected and 
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656 concentrations of a series of pro-inflammatory chemokines, cytokines, and adhesive molecules in 
657 the supernatants were determined by Quantikine ELISA kits (R&D Systems, Minneapolis, MN) 
658 according to the manufacturer’s instructions (67). All assays were performed in triplicates.
659 Statistical analysis. Quantitative data are expressed as mean SEM or SD.  Differences among 
660 three or more groups were statistically analyzed by one or two-way ANOVA followed by 
661 Bonferroni's post-hoc test.  Comparisons between two experimental groups were conducted by 
662 the two-tailed Student’s t-test. A p-value less than 0.05 was considered significant. Statistical 
663 analyses and graphic representations were obtained with GraphPad Prism 7.0 software.
664
665 Data availability statement
666 The authors confirm that the data supporting the findings of this study are available within the 
667 article and from the corresponding author upon reasonable request. 
668
669 Abbreviation: Endothelial cell = EC; Krüppel-like factor = KLF; Blood-brain barrier = BBB; 
670 Peroxisome proliferator-activated receptor gamma = PPARγ; Tight junction = TJ; Brain 
671 microvascular endothelial cells = BMECs; Oxygen-Glucose Deprivation = OGD; 
672 Transepithelial/transendothelial electrical resistance (TEER); Middle cerebral artery occlusion = 
673 MCAO; 2,3,5-triphenyltetrazolium chloride = TTC; Cerebral blood flow = CBF; Microtubule-
674 associated protein 2 = MAP2.Reference
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891 Figure 1. Generation of endothelial cell (EC)-selective KLF11 transgenic mice. (A) Schematic 
892 diagram of EC-selective KLF11 transgenic structure. The transgene cassette is composed of a 
893 ~2.1-kb Tie-2 promoter, a ~10.4-kb Tie-2 enhancer, and a 1539-bp DNA fragment containing the 
894 human KLF11 coding sequence. (B) Genomic PCR for genotyping EC-selective KLF11 
895 transgenic mice (EC-KLF11 Tg). A 960 bp band is expected from EC-KLF11 transgenics (Lanes 
896 1, 3, and 16). (C) Representative western blotting images indicated enhanced protein levels of 
897 KLF11 in the cerebral microvessels (cerebral vessels, left) but not in brain parenchyma (cerebral 
898 cortex, right) of EC-KLF11 Tg mice than WT controls. n=5 mice per group. (D) Representative 
899 immunofluorescent images show CD31-positive capillaries in the cortex and striatum of both 
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901 CD31-labeled branch points, capillary numbers, and branch length are shown. In comparison 
902 with WT controls, EC-targeted transgenic overexpression of KLF11 does not affect cerebral 
903 vascular density and structure in mice. Data are expressed as mean ±SEM.
904 Figure 2. Targeted overexpression of KLF11 in endothelium ameliorates both early- and late-
905 onset BBB impairments, edema, and neutrophil infiltration. EC-KLF11 Tg mice and WT 
906 controls were subjected to 1 h MCA occlusion followed by 1, 3, or 24 h reperfusion. (A) 
907 Extravasation of Evans blue dye and (B) 70 kDa TMR-Dextran 24 h after MCAO in whole 
908 brains or coronal sections was shown. Scale bar, 50 µm. (C-D) Quantification of Evans blue in 
909 panel A and TMR-Dextran in panel B. n=6 mice per group. (E) Representative images 
910 demonstrate the extravasation of Alexa Fluor 555 (0.95 kDa, red) or endogenous plasma IgG 
911 (~150 kDa, green) into brain parenchyma 1, 3, or 24 h after MCAO. At 24 h after MCAO, the 
912 area with loss of microtubule-associated protein 2 (MAP2) immunofluorescence illustrates the 
913 infarct zone on adjacent sections from the same brains. (Scale bar: 1 mm). (F-G) Quantitative 
914 analysis of the volume of the brain with leakage of cadaverine and IgG at indicated times of 
915 reperfusion after MCAO.  n=5 mice per group. (H) Brain infarct volume at 24 h after MCAO 
916 was quantitatively measured on MAP2-stained coronal sections. n=5 mice per group. (I) Brain 
917 water content was measured by the wet/dry weight protocol as described in the “Material and 
918 Methods”. n=10 per group, ** p < 0.01 vs. WT contralateral hemisphere, # p < 0.05 vs. WT 
919 ipsilateral hemisphere. (J) Representative images taken from the ipsilateral periinfarct cortex 
920 after MCAO or the corresponding region after sham operation; markers used: Ly-6B (neutrophil), 
921 and NeuN (neuron) (Scale bar: 50 μm). Rectangle: the region enlarged in high-power images 
922 (third column). (Scale bar: 10 µm.) (K) Ly-6B+ cells were counted in the areas described in (J) 
923 and data are expressed as the number of cells per mm2. After MCAO, the number of infiltrated 
924 neutrophils is significantly less in EC-KLF11 Tg mouse brains compared with WT controls. n=5 
925 mice per group. Data are expressed as mean ± SEM. * p < 0.05 vs. WT + sham group, # p < 0.05 
926 vs. WT + MCAO group.
927 Figure 3. Transgenic overexpression of KLF11 in endothelium improves short-term histological 
928 and functional outcomes after focal cerebral ischemia. (A) EC-KLF11 Tg mice and WT controls 
929 were subjected to 1 h MCAO and 72 h reperfusion. Two percent TTC-stained coronal sections 
930 were shown at different brain levels from the frontal to the posterior pole. (B) Quantitative 
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932 ischemic stroke. n= 8 mice per group. (D) Regional CBF was measured by using a laser speckle 
933 imager. EC-KLF11 Tg and WT mice were subjected to 1 h MCAO followed by 72 h reperfusion. 
934 Representative CBF images were shown at 15 min before MCAO (baseline), 15 min after the 
935 onset of MCAO (ischemia), and 15 min after the onset of reperfusion (reperfusion). (E) Two 
936 identical elliptical ROIs were selected as indicated on the same brain region of the ipsilateral and 
937 contralateral hemispheres. The relative CBF was first determined as the ratio of ischemic to 
938 nonischemic cerebral blood flow, and then as the percentage value normalized to the presurgical 
939 baseline for each animal. n=6 each group. (F-I) Sensorimotor deficits were assessed before and 
940 up to 7 days after MCAO by a battery of behavioral tests, including Rotarod test (F), Foot fault 
941 (G), and Adhesive tape removal test (H-I). Compared with WT controls, mice with endothelial-
942 specific overexpression of KLF11 showed dramatically improved sensorimotor function 
943 (increased staying latency in the rotarod test, lower rate of fault steps in the foot fault test, and 
944 shorter touching or removing time in the adhesive tape removal test. Data are represented as 
945 mean ± SD. n=12 per group. * p < 0.05, ** p < 0.01, *** p < 0.001 EC-KLF11 Tg MCAO vs. 
946 WT MCAO by one-way ANOVA (individual time point) or two-way ANOVA (bracket).
947 Figure 4. EC-targeted KLF11 overexpression preserves the integrity of tight junctions after focal 
948 cerebral ischemia. EC-KLF11 Tg mice and WT controls were subjected to 1 h MCA occlusion 
949 and 1d or 3d reperfusion. (A-B) Total RNA was extracted from the ipsilateral cortex of EC-
950 KLF11 Tg and WT mice 1d and 3d after MCAO. ZO-1 and occludin mRNA expression levels 
951 were determined by qPCR and normalized to cyclophilin (n=6 per group). (C) Total protein was 
952 extracted and subjected to gel electrophoresis. The protein levels of ZO-1 and occludin were 
953 determined with β-actin as the loading control. (D-E) Quantification of ZO-1 and occludin 
954 protein. Experiments were repeated three times and representative blots are displayed. n=6 per 
955 group. (F) Representative images and quantification of ZO-1 (green) and occludin (green) on 
956 CD31+ microvessels (red) in the cortex of the ischemic hemisphere at 1d after MCAO. (Scale 
957 bar: 25 µm.) Endothelial KLF11 overexpression suppressed MCAO-induced disruption of 
958 junctional proteins ZO-1 and occludin. n=6 mice per group. * p < 0.05 vs. WT + sham group, # p 
959 < 0.05 vs. WT + MCAO group.
960 Figure 5. Effects of EC-targeted overexpression of KLF11 on inflammatory mediators in mouse 
961 cortex after focal cerebral ischemia. EC-KLF11 Tg and WT mice were subjected to sham 
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963 of different inflammatory markers were measured in the ipsilateral cortex by qPCR and 
964 normalized to cyclophilin. (G-L) Protein levels of different inflammatory markers were analyzed 
965 by ELISA. EC-targeted overexpression of KLF11 inhibited MCAO-induced upregulation of 
966 TNFα, IL-1β, MCP-1, IL-6, ICAM-1, and P-selectin expression. n=6 mice per group. * p < 0.05 
967 vs. WT + sham group, # p < 0.05 vs. WT + MCAO group.
968 Figure 6. Adenoviral gain- or loss-of-KLF11 expression in mouse BMECs affects endothelial 
969 barrier function after OGD in vitro. (A) Illustration of the transwell co-culture system. Mouse 
970 astrocytes were seeded at the bottom of a 12-well plate with transwell insert. Cultured mBMECs 
971 were seeded on top of a collagen- and fibronectin-coated membrane of the insert and grown to 
972 form a confluent monolayer. The mBMECs were infected for 48 h with either an empty 
973 adenovirus (Ad. LacZ), adenoviral vector carrying mouse KLF11 (Ad. KLF11), adenoviral 
974 vector shLacZ (Ad. shLacZ), or adenoviral vector carrying short hairpin sequences targeting 
975 mouse KLF11 (Ad. shKLF11), and then subjected to OGD for 16 h before being placed back to 
976 the plate with astrocytes. (B-C) Transepithelial electrical resistance (TEER) in the co-culture 
977 model was measured at 2 h after OGD and in non-OGD conditions. n=3 per group, * p < 0.05 vs. 
978 Ad. LacZ/Ad. shLacZ + non-OGD group, # p < 0.05 vs. Ad LacZ/Ad. shLacZ + 16h OGD-2h 
979 Reoxygenation. (D-E) Paracellular permeability was quantified at 0–24 h after OGD by 
980 measuring the fluorescence intensity of abluminal Dextran Alexa Fluor 488 (3,000 MW). 
981 Adenovirus-mediated KLF11 overexpression improved endothelial barrier function after OGD 
982 treatment, whereas KLF11 knockdown worsened endothelial barrier function. Data are expressed 
983 as mean ± SEM of three independent experiments with triplicate wells (n=3 per group). * P < 
984 0.05 vs. Ad. LacZ/Ad. shLacZ + 16h OGD group.
985 Figure 7. Adenovirus-mediated KLF11 overexpression in mouse BMEC cultures preserves the 
986 integrity of tight junction proteins after OGD. Cultured mBMECs were infected with Ad. LacZ 
987 or Ad. KLF11 for 48 h prior to 16 h or 4 h OGD followed by 24 h or 48 h reperfusion. (A-B) The 
988 mRNA expression levels of ZO-1 and occludin were determined by qPCR and normalized to 
989 cyclophilin (n=3 per group). (C-D) Expression levels of tight junction proteins, ZO-1 and 
990 occludin were evaluated by western blotting. β-Actin was used as an internal loading control. 
991 Data represent three independent experiments and representative blots are displayed. n=3 per 
992 group. * P < 0.05 vs. Ad. LacZ + non-OGD group, # P < 0.05 vs. Ad. LacZ + OGD group. (E) 
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994 mBMECs after 4 h OGD, followed by 24 h reoxygenation. (Scale bar: 25 µm.) Adenoviral 
995 KLF11 overexpression suppressed OGD-induced disruption of junctional proteins, ZO-1, and 
996 occludin. n=3 per group. * P < 0.05 vs. Ad. LacZ + non-OGD group, # P < 0.05 vs. Ad. LacZ + 
997 OGD group. H16R0 = 16h OGD + 0h reperfusion, H16R24 = 16h OGD + 24h reperfusion, 
998 H16R48 = 16h OGD + 48h reperfusion, H4R0 = 4h OGD + 0h reperfusion, H4R24 = 4h OGD + 
999 24h reperfusion.
1000 Figure 8. KLF11 transcriptionally activates ZO-1 and occludin. (A) Potential KLF11 binding 
1001 site in the promoter region of mouse ZO-1 and occludin. TSS: transcription start site. The green 
1002 triangles mark the binding sites of KLF11. The numbers indicate the relative distance to TSS, 
1003 which is labeled as +1. (B) 1kb of the mouse ZO-1 promoter or a mutated ZO-1 promoter 
1004 (deleted all three KLF11 binding sequences, Δ mZO-1) was cloned into the pGL4.10[luc2] 
1005 vector. The pGL4 promoter constructs were then transfected into bEnd.3 cultures. bEnd.3 cells 
1006 were also co-transduced with an empty adenovirus (Ad. LacZ) or adenoviral vectors carrying 
1007 mouse KLF11 (Ad. KLF11) for 48-72 h prior to performing luciferase reporter activity assays. 
1008 (C) KLF11 overexpression in bEnd.3 cells significantly increased luciferase activity of 
1009 pGL4_mZO-1, which contains all three KLF11 binding sequences (n=4 per group). (D) On the 
1010 contrary, the luciferase activity was significantly reduced in the pGL4_mZO-1 group co-
1011 transfected with Ad. shKLF11 (n=4 per group). (E) The occludin promoter or a mutated occludin 
1012 promoter (deleted all three KLF11 binding sequences, Δ mOccludin) was cloned into the 
1013 pGL4.10[luc2] vector. (F) KLF11 overexpression significantly increased luciferase activity of 
1014 pGL4_mOccludin, but not pGL4_Δ mOccludin (n=4 per group). (G) On the contrary, luciferase 
1015 activity was significantly reduced in the pGL4_mOccludin group co-transfected with Ad. 
1016 shKLF11 (n=4 per group). Results shown are representative of three separate experiments with 
1017 similar results. Data are expressed as mean ± SEM. * P < 0.05 vs. Ad. LacZ group or Ad. 
1018 shLacZ group.
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